- Founded: 2015
- CEO: Timothy Fischer
- Size of Facility: 5500 sq ft
- Company Size: 20
- Funding Source: Grants (e.g. SBIR, CRCF, CIT), Investor Funded
- Development Stage: Pre-clinical
HemoSonics is bringing to market a next-generation point-of-care diagnostic platform, the Quantra™, that provides actionable information to guide the management of critical bleeding and clotting.
The goal is to improve outcomes and reduce healthcare costs by enabling more targeted selection and dosing of blood products in critical settings. HemoSonics seeks to transform the way clinicians manage coagulation dysfunctions by providing comprehensive, timely and accurate information on coagulation status at the point of care, enabling clinicians to choose rapidly the right treatment, dramatically improving outcomes and lowering treatment costs.